Jefferies Assumes Pyxis Oncology at Buy, Announces Price Target of $10
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Farzin Haque has initiated coverage on Pyxis Oncology (NASDAQ:PYXS) with a Buy rating and set a price target of $10.

May 07, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies has initiated coverage on Pyxis Oncology with a Buy rating and a price target of $10.
The initiation of coverage by Jefferies with a Buy rating and a price target significantly above the current trading price is likely to be viewed positively by the market. This endorsement from a reputable analyst could lead to increased investor confidence and demand for PYXS shares, potentially driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100